Ads
related to: alternative therapy for multiple myeloma locations- Treatment Schedule
Learn How This Treatment Is Given
See the Infusion Schedule
- Phase 3 Trials
See Study Results
From the Latest Trial
- Resources
Download Helpful Resources
for Patients and Caregivers
- Safety Information
Read Safety Information
for Patients and Caregivers
- Treatment Schedule
Search results
Results From The WOW.Com Content Network
Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma. [3] [7] [8]The most common side effects include cytokine release syndrome (CRS), infections, fatigue, musculoskeletal pain, and a weakened immune system (hypogammaglobulinemia).
The major application of CAR-T immunotherapy is to treat hematological malignancies, such as multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia and lymphoma. [8] Also, CAR-T-related solid tumor treatments have become increasingly promising due to protein and cell engineering improvements. [9]
A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107] There are two types of stem cell transplants to treat multiple myeloma. [108] In autologous hematopoietic stem-cell transplantation (ASCT) – the patient's stem cells are collected from the patient's blood. The patient is given high-dose ...
Omacetaxine mepesuccinate (a drug approved for the treatment for chronic myelogenous leukemia) and Seliciclib [12] (which is under investigation as a potential multiple myeloma treatment) both act in part by inhibiting synthesis of Mcl-1. MCL1 has been identified as a resistance factor for BCL-2 inhibitor venetoclax in lymphoma cells.
acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences 07-16-1998 Thalomid: thalidomide (in combination with dexamethasone) treatment of patients with newly diagnosed multiple myeloma 05-25-2006
In December 2012, it was reported that 10 of 13 patients with multiple myeloma were in remission "or very close to it" three months after being injected with a treatment involving genetically engineered T cells to target proteins NY-ESO-1 and LAGE-1, which exist only on cancerous myeloma cells. [28]
Ads
related to: alternative therapy for multiple myeloma locations